Kazia Therapeutics Limited American Depositary Shares KZIA
i
Market datapartial · fetched 2026-11-04T08:52:44.758Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-11-20
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-03T21:00:00.660641151Z
FundamentalsAlpha Vantage · unavailable
Kazia Therapeutics Limited American Depositary Shares options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | ||||||
| 25Δ | ||||||
| 30Δ | ||||||
| 35Δ | 7.54 | 156.3% | 16.4% | |||
| 40Δ | 8.05 | 168.4% | 15.1% | |||
| 45Δ | 8.56 | 180.5% | 13.8% | |||
| 50Δ | 9.06 | 192.7% | 12.6% | |||
| 55Δ | 15.57 | 599.7% | 123.6% | 9.57 | 204.8% | 11.3% |
| 60Δ | 10.50 | 473.7% | 60.9% | 10.06 | 213.2% | 10.0% |
| 65Δ | 10.47 | 201.5% | 8.5% | |||
| 70Δ | 7.07 | 201.5% | 11.2% | 10.88 | 189.8% | 7.0% |
| 75Δ | 6.62 | 195.9% | 9.1% | 11.29 | 178.1% | 5.5% |
| 80Δ | 6.17 | 190.4% | 7.0% | 11.70 | 166.4% | 4.0% |
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- IV
- B/E move
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 7.54
- IV
- 156.3%
- B/E move
- 16.4%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.05
- IV
- 168.4%
- B/E move
- 15.1%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 8.56
- IV
- 180.5%
- B/E move
- 13.8%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 9.06
- IV
- 192.7%
- B/E move
- 12.6%
55Δ
- Pseudo strike
- 15.57
- IV
- 599.7%
- B/E move
- 123.6%
- Pseudo strike
- 9.57
- IV
- 204.8%
- B/E move
- 11.3%
60Δ
- Pseudo strike
- 10.50
- IV
- 473.7%
- B/E move
- 60.9%
- Pseudo strike
- 10.06
- IV
- 213.2%
- B/E move
- 10.0%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 10.47
- IV
- 201.5%
- B/E move
- 8.5%
70Δ
- Pseudo strike
- 7.07
- IV
- 201.5%
- B/E move
- 11.2%
- Pseudo strike
- 10.88
- IV
- 189.8%
- B/E move
- 7.0%
75Δ
- Pseudo strike
- 6.62
- IV
- 195.9%
- B/E move
- 9.1%
- Pseudo strike
- 11.29
- IV
- 178.1%
- B/E move
- 5.5%
80Δ
- Pseudo strike
- 6.17
- IV
- 190.4%
- B/E move
- 7.0%
- Pseudo strike
- 11.70
- IV
- 166.4%
- B/E move
- 4.0%
Options history
Table
| Date | IV (%) |
|---|---|
| 167.28% |
Biotechnology
LBRX
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases.…
More →LCTX
Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment of degenerative diseases in the…
More →LEGN
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in…
More →LENZ
Description unavailable
More →LGND
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies discover and develop drugs…
More →LITS
Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. The company is headquartered in San…
More →